Beijing-based orthopaedic device maker CHUNLI MEDICAL reported mixed interim results for the six months ended 30 June 2026. Revenue fell 14.46 % year on year to RMB 417.10 million (USD 57.4 million), largely reflecting slower domestic demand amid ongoing volume-based procurement for high-value orthopaedic consumables. The revenue decline was driven almost entirely by the core medical-device segment, which dropped 14.41 % to RMB 416.87 million.

\n\n

Despite top-line pressure, cost discipline underpinned profit growth. Selling expenses were cut by 31.67 % to RMB 65.78 million, and administrative costs fell 31.09 % to RMB 19.56 million. Research and development outlays eased 7.14 % to RMB 47.23 million but still accounted for 11.3 % of sales, underscoring management’s focus on product innovation.

\n\n

Net profit attributable to shareholders rose 4.79 % to RMB 119.96 million (USD 16.5 million), aided by lower operating expenses and a favourable sales mix. The net margin expanded to 28.8 % from 23.5 % a year earlier.

\n\n

The balance sheet remained robust. Cash and cash equivalents stood at RMB 1.38 billion, only 2.01 % below year-end 2025, while total liabilities contracted 19.6 % to RMB 541.76 million, driving the gearing ratio down to 15.1 % from 18.4 %. The company continues to deploy surplus funds into short-term, low-risk structured deposits; unredeemed positions totalled RMB 725.06 million at period-end.

\n\n

Capital expenditure was negligible in the half, but CHUNLI MEDICAL maintained R&D momentum, holding 760 domestic intellectual-property rights and 237 medical-device registration certificates. The pipeline was strengthened by approvals across joint, spine, sports-medicine, trauma and dental segments, while the company’s handheld orthopaedic surgical robot received added certifications.

\n\n

The Board approved an interim cash dividend of RMB 1.30 per 10 shares, amounting to RMB 49.68 million, equivalent to a 41.4 % payout of first-half attributable profit. The proposal awaits shareholder approval at an upcoming extraordinary general meeting.

\n\n

Management reiterated its strategy to mitigate procurement pressure through product diversification, sustained innovation investment and further international expansion, supported by a liquidity position it regards as ample for foreseeable capital needs.